Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

viggizags Jul. 7 at 6:29 AM

$SPY right now the saying is boring is exciting insurance killing it, banks killing it, character changes in a stock like $KMB one of the better performers this year is Woody Johnson coin $JNJ even better going out YoY. Had a joker laughing at me because i was posting about $C again boring is exciting. Tons of opportunity out there, even if the index turns down plenty if long opportunities.

0 · Reply

DidYouReadThis Jul. 7 at 5:55 AM

#DoYouWantToBuildASnowman? $DIS or try to #SetACommentRecord? $TSLA $AMC $JNJ $NAK . On original post please <3

0 · Reply

parcha Jul. 7 at 12:40 AM

Jim Cramer says these are the 5 stocks to buy during this market rotation $JNJ $PEP $SBUX $TJX CNBC’s Jim Cramer said investors should use the latest market rotation as an opportunity to buy high-quality companies that were swept lower by broad institutional selling. He highlighted Johnson & Johnson, PepsiCo, Starbucks, Constellation Brands and TJX as stocks that he thinks were unfairly caught up in the move. https://www.cnbc.com/2026/07/06/jim-cramer-stocks-buy-during-market-rotation.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension

0 · Reply

TroyTiger Jul. 7 at 12:22 AM

$TGTX $JNJ is an obvious buyout partner here. MW get this done...

1 · Reply

ElliottwaveForecast Jul. 7 at 12:14 AM

Do you actually know what confirms continuation in $JNJ before price breaks out? The bullish sequence remains active, pointing toward 271.37 and higher levels. Check out this 👉 https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #JNJ #trading #forecasting

0 · Reply

clan Jul. 6 at 8:23 PM

$ELTP With 2 upcoming cash-generating profitable quarters to be reported [early Aug and Nov], Elite stock will get up to > $1/sh by yr. end, just on operational output alone. Yes, a triple from here to 12/31/26. 💊💵 #drugmoney Take a look-see 👀 $TEVA $JNJ #pillpopper

1 · Reply

TraderDaKing Jul. 6 at 7:31 PM

$GME $JNJ $WEN

0 · Reply

BarkingPuppy Jul. 6 at 6:30 PM

$ELTP $JNJ $PFE $GME

0 · Reply

TraderDaKing Jul. 6 at 6:16 PM

$ELTP $JNJ $PFE $GME Big Pharma moving in to grab the best kept secret out of New Jersey. Quarterly swing from loss to profit through FY 2026 Across FY 2026, Elite Pharmaceuticals moved from a basic EPS loss of US$0.0055 in Q1, when net income excluding extra items was a loss of US$5.9 million on US$40.2 million of revenue, to positive basic EPS in the remaining quarters, ending Q4 with basic EPS of US$0.0171 and net income excluding extra items of US$18.5 million on US$40.7 million of revenue.

0 · Reply

TraderDaKing Jul. 6 at 5:21 PM

$ELTP $JNJ $PFE $MRNA $GME Understand the Technology Behind SequestOxAbuse-Deterrent Mechanism: It is an immediate-release oxycodone hydrochloride that encapsulates a hidden, sequestered core of naltrexone.Intended Use: When swallowed normally, the naltrexone passes unabsorbed through the body while the oxycodone treats pain.Abuse Defeat: If the pill is crushed or dissolved for snorting or injecting, the naltrexone is unleashed.Euphoria Block: Free naltrexone aggressively blocks opioid brain receptors, completely stripping away the drug's euphoric high. ROARING KITTY MAKING HIS MOVE. Elite is the New MEME stock.

0 · Reply

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

2026-07-06T14:25:32.000Z - 17 hours ago

Johnson & Johnson price target raised to $290 from $280 at HSBC

Jun 26, 2026, 2:39 PM EDT - 10 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

2026-06-26T16:40:11.000Z - 10 days ago

Johnson & Johnson presents new Imaavy data at EAN 2026 Congress

Jun 26, 2026, 12:35 PM EDT - 10 days ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

2026-06-26T12:36:03.000Z - 10 days ago

Johnson & Johnson price target raised to $270 from $266 at Guggenheim

2026-06-25T09:10:22.000Z - 11 days ago

Johnson & Johnson launches Dual Energy Thermocool Smarttouch in Europe

Jun 25, 2026, 5:00 AM EDT - 11 days ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

2026-06-16T20:26:11.000Z - 20 days ago

3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026

AMCR LOW

2026-06-15T11:17:46.000Z - 21 days ago

Johnson & Johnson (JNJ) Boosts Eye Care Business in $55B U.S. Manufacturing Push

2026-06-15T10:05:07.000Z - 21 days ago

Johnson & Johnson invests more than $1B in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 21 days ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 23 days ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 23 days ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

2026-06-11T11:50:10.000Z - 25 days ago

Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL

Jun 11, 2026, 7:45 AM EDT - 25 days ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:14 AM EDT - 25 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

2026-06-11T09:26:54.000Z - 25 days ago

Johnson & Johnson presents first results from ENERGY study

Jun 11, 2026, 2:03 AM EDT - 26 days ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 26 days ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 26 days ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 27 days ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 27 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 4 weeks ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 8:08 AM EDT - 4 weeks ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 5, 2026, 6:24 PM EDT - 4 weeks ago

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 3, 2026, 12:04 AM EDT - 4 weeks ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Jun 3, 2026, 12:03 AM EDT - 4 weeks ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 2, 2026, 6:24 PM EDT - 4 weeks ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

May 31, 2026, 8:39 AM EDT - 5 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:29 AM EDT - 5 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:27 AM EDT - 5 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:01 AM EDT - 5 weeks ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 29, 2026, 2:00 PM EDT - 5 weeks ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 8:18 AM EDT - 5 weeks ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 28, 2026, 7:10 PM EDT - 5 weeks ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 5:30 AM EDT - 5 weeks ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 27, 2026, 4:22 PM EDT - 5 weeks ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 11:00 AM EDT - 5 weeks ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 21, 2026, 7:00 AM EDT - 6 weeks ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 4:31 AM EDT - 6 weeks ago

Johnson & Johnson says nipocalimab approved in China

May 19, 2026, 11:30 AM EDT - 6 weeks ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 9:00 AM EDT - 6 weeks ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 14, 2026, 4:01 PM EDT - 7 weeks ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

May 12, 2026, 2:20 PM EDT - 7 weeks ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:45 AM EDT - 7 weeks ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 11, 2026, 4:34 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 7, 2026, 11:34 AM EDT - 2 months ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 5, 2026, 9:15 AM EDT - 2 months ago

CVS to drop J&J's Stelara from its main formularies

CVS

May 5, 2026, 8:05 AM EDT - 2 months ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

$Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease$

May 5, 2026, 8:05 AM EDT - 2 months ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 7:00 AM EDT - 2 months ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 4, 2026, 8:00 AM EDT - 2 months ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 2, 2026, 4:00 AM EDT - 2 months ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Apr 30, 2026, 8:02 AM EDT - 2 months ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 28, 2026, 11:10 AM EDT - 2 months ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Apr 27, 2026, 4:33 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 11:03 AM EDT - 2 months ago

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 8:03 AM EDT - 2 months ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 24, 2026, 4:30 PM EDT - 2 months ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

viggizags Jul. 7 at 6:29 AM

0 · Reply

DidYouReadThis Jul. 7 at 5:55 AM

#DoYouWantToBuildASnowman? $DIS or try to #SetACommentRecord? $TSLA $AMC $JNJ $NAK . On original post please <3

0 · Reply

parcha Jul. 7 at 12:40 AM

0 · Reply

TroyTiger Jul. 7 at 12:22 AM

$TGTX $JNJ is an obvious buyout partner here. MW get this done...

1 · Reply

ElliottwaveForecast Jul. 7 at 12:14 AM

0 · Reply

clan Jul. 6 at 8:23 PM

1 · Reply

TraderDaKing Jul. 6 at 7:31 PM

$GME $JNJ $WEN

0 · Reply

BarkingPuppy Jul. 6 at 6:30 PM

$ELTP $JNJ $PFE $GME

0 · Reply

TraderDaKing Jul. 6 at 6:16 PM

0 · Reply

TraderDaKing Jul. 6 at 5:21 PM

0 · Reply

Stockprofiler Jul. 6 at 5:13 PM

$AIMN The right network. The right context. @AimwellBIO Observer connects serious healthcare professionals to trusted signals, curated intelligence, and a verified network built for the future of healthcare. Apply free. Stay in the network. http://aimwellbio.com/observer-signup $AIMN #pharma $PFE $JNJ $MEDI

0 · Reply

clan Jul. 6 at 4:37 PM

$MNKD 's Furoscix Readyflow AutoInjector will make Order-Takers out of MannKind's Sales Reps. $JNJ $PFE $MRK Golden goose egg.

0 · Reply

BarkingPuppy Jul. 6 at 2:33 PM

$ELTP $PFE $JNJ $MRNA $GME Elite SequestOx is an investigational abuse-deterrent opioid formulation developed by Elite Pharmaceuticals. It combines oxycodone hydrochloride with sequestered naltrexone hydrochloride, designed to manage moderate to severe pain while reducing the potential for abuse. The drug has been under development and review by the FDA, with Elite Pharmaceuticals reporting positive study results and ongoing efforts to address regulatory feedback. SequestOx aims to change pain management by providing effective opioid pain relief with built-in abuse deterrence, which could significantly impact how opioids are prescribed and used, potentially reducing opioid misuse and addiction risks. This is going Crazy people...... Elite Pharma from New Jersey.

0 · Reply

TraderDaKing Jul. 6 at 1:38 PM

$PFE $JNJ $MRNA Something is going on with Elite. ELTP is in play..

0 · Reply

TraderDaKing Jul. 6 at 1:11 PM

$WULF $BAC $PFE $JNJ Deal coming

0 · Reply

ElliottwaveForecast Jul. 6 at 11:02 AM

$JNJ continue rally targeting 271.4 - 305.3 area against 6.23.2026 low It is bullish in daily & expect rally within January-2025 low to continue against May-2026 low. Short term pullback in 3, 7 or 11 swings remain supported. https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ

0 · Reply

cheeze_13 Jul. 6 at 3:56 AM

$JNJ also has a nice break & retest of ATH at $251.71; also has BOS at $259.93 with rising volume & riding the 8 EMA as well. Exact same setup as $MRK, could be better or not but both can go tomorrow. Overnight price is sitting at $262.61. Entry will be break & hold above PDH at $263.10 & looking to exit around $267.50 or sooner if price catches resistance. Trim & leave runners for this play

1 · Reply

ShKumaresan Jul. 6 at 3:47 AM

$NAVN $JNJ $CRWD NAVN, JNJ, CRWD Stocks Hit 52-Week Highs Last Week: What's Driving The Surge? https://stocktwits.com/news-articles/markets/equity/navn-jnj-crwd-stocks-hit-52-week-highs-last-week-what-s-driving-the-surge/cZmKzcAR7kn

0 · Reply

StocktwitsNews Jul. 6 at 3:46 AM

NAVN, JNJ, CRWD Stocks Hit 52-Week Highs Last Week: What's Driving The Surge? $NAVN $JNJ $CRWD https://stocktwits.com/news/equity/markets/navn-jnj-crwd-stocks-hit-52-week-highs-last-week-what-s-driving-the-surge/cZmKzcAR7kn

0 · Reply

GordoHLYK13 Jul. 5 at 1:15 PM

$IGC $JNJ $LLY $PFE $IGC is still valued around a ~$30M market cap. If Phase 2 CALMA delivers strong topline results, management believes the company could be re-rated closer to peers at a $300M–$500M valuation. That’s a potential 10x–16.6x increase in market value. Using a ~$0.27 share price as a baseline, that equates to roughly $2.70–$4.50 per share. Phase 2 data is the key catalyst that could determine whether the market assigns that higher valuation.

0 · Reply

GordoHLYK13 Jul. 5 at 1:00 PM

$IGC $IGC is flying under the radar. 🧠 Phase 2 IGC-AD1/CALMA is nearing completion with topline data expected in the coming months. A patented, easy-to-administer liquid therapy has shown rapid Phase 2 efficacy in as little as 2 weeks for Alzheimer’s agitation. With a market cap around $30M, low cash burn, a massive unmet market, and peer biotechs historically re-rating 10x+ on positive Phase 2 data, the risk/reward is hard to ignore. Eyes on the catalyst. 🚀 $LLY $BIIB $JNJ $PFE #Alzheimers #Biotech https://youtu.be/87NG8ioxSw4?is=AY9ZnJw5__5pn_fM

0 · Reply

ElliottwaveForecast Jul. 5 at 9:19 AM

📢 $JNJ Bullish Rally Targets $271.37+ 💊 Johnson & Johnson is unfolding a strong Elliott Wave bullish sequence. The structure favors continued upside, with momentum pointing toward $271.37 and beyond as the cycle extends higher. 📈 Read the Full analysis of JNJ bullish cycle 👉 https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #ElliottWave #Trading #Stocks

0 · Reply

Market Cap	633.19B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	23.67
Forward PE	22.74
Profit Margin	28.46%
Debt to Equity Ratio	0.46

Volume	6,803,700
Avg Vol	8,154,996
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	87%
Beta	0.24
Analysts	Strong Sell
Price Target	$260.04